Published in J Am Soc Nephrol on February 18, 2009
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34
Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care (2013) 1.31
Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ (2016) 1.30
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol (2010) 1.16
Epigenetics in diabetic kidney disease. J Am Soc Nephrol (2011) 1.09
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One (2013) 1.03
Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol (2013) 0.98
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: the lower, the better? Diabetes Care (2011) 0.90
Therapeutic management of diabetic kidney disease. J Diabetes Investig (2011) 0.90
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Health care costs in people with diabetes and their association with glycemic control and kidney function. Diabetes Care (2012) 0.89
Documentation and management of CKD in rural primary care. Clin J Am Soc Nephrol (2013) 0.86
Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care (2011) 0.86
Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am (2013) 0.86
Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol (2014) 0.85
Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D (2014) 0.84
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc Nephrol (2011) 0.84
Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care (2013) 0.84
Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis (2015) 0.84
Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes (2014) 0.83
Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian J Nephrol (2011) 0.83
Therapeutic Modalities in Diabetic Nephropathy: Future Approaches. Open J Nephrol (2012) 0.81
Type 2 diabetes in older people; the importance of blood pressure control. Curr Cardiovasc Risk Rep (2013) 0.79
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Suppl (2011) (2012) 0.79
Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. J Endocrinol (2014) 0.78
Blood pressure and pulse pressure effects on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care (2014) 0.77
Systolic blood pressure and outcomes in stage 3-4 chronic kidney disease patients: evidence from a Taiwanese cohort. Am J Hypertens (2014) 0.77
Chronic kidney disease: Blood pressure control in CKD--still a matter of debate. Nat Rev Nephrol (2013) 0.76
Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease. Physiol Rep (2017) 0.75
Diabetes: Glycemic and blood-pressure control--lower is not better. Nat Rev Nephrol (2012) 0.75
Improved incidence of end-stage renal disease of type 1 diabetes in Japan, from a hospital-based survey. BMJ Open Diabetes Res Care (2016) 0.75
Management of Diabetic Nephropathy in the Elderly: Special Considerations. J Nephrol Ther (2012) 0.75
Relationship between history of coronary heart disease at dialysis initiation and onset of events associated with heart disease: a propensity-matched analysis of a prospective cohort study. BMC Nephrol (2017) 0.75
Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. High Blood Press Cardiovasc Prev (2013) 0.75
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. J Clin Med (2015) 0.75
Diabetes: Renal benefits of lowering BP in the absence of hypertension. Nat Rev Nephrol (2009) 0.75
[Treatment of hypertension in diabetic patients]. Wien Med Wochenschr (2010) 0.75
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Standards of medical care in diabetes--2008. Diabetes Care (2008) 17.23
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med (1994) 11.65
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med (2001) 10.36
Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc (1985) 7.02
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Blood pressure and end-stage renal disease in men. N Engl J Med (1996) 5.68
The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med (2005) 5.45
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int (2003) 5.37
Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med (1999) 4.82
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med (2005) 3.44
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis (2000) 3.37
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int (2002) 3.10
Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med (1988) 2.62
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med (2003) 2.45
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens (2006) 2.37
Progression of nephropathy in type 2 diabetic patients. Kidney Int (2004) 2.05
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney Int (2006) 1.80
Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant (2004) 1.49
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med (1998) 1.26
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension (2003) 0.98
Renal response to angiotensin-converting enzyme inhibition. Am J Cardiol (1982) 0.92
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens (2007) 0.85
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 18.36
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet (2007) 13.62
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Avoidable waste in the production and reporting of research evidence. Lancet (2009) 12.28
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med (2012) 11.83
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
Point: cardiovascular variability is/is not an index of autonomic control of circulation. J Appl Physiol (1985) (2006) 11.52
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 11.10
Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med (2009) 9.77
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA (2003) 9.06
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol (2008) 7.45
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ (2005) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet (2009) 6.39
Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet (2010) 6.36
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med (2004) 6.26
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet (2013) 6.19
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int (2011) 6.01
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet (2006) 5.83
Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med (2010) 5.80
Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension (2003) 5.63
Chronic diseases now a leading cause of death in rural India--mortality data from the Andhra Pradesh Rural Health Initiative. Int J Epidemiol (2006) 5.60
Management of hypertension: summary of NICE guidance. BMJ (2011) 5.60
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet (2008) 5.49
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet (2009) 5.43
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol (2008) 5.40
Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet (2011) 5.33
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25